SI1660491T1 - Benzimidazolni, benztiazolni in benzoksazolni derivati in njihova uporaba kot modulatorji LTA4H - Google Patents

Benzimidazolni, benztiazolni in benzoksazolni derivati in njihova uporaba kot modulatorji LTA4H

Info

Publication number
SI1660491T1
SI1660491T1 SI200430904T SI200430904T SI1660491T1 SI 1660491 T1 SI1660491 T1 SI 1660491T1 SI 200430904 T SI200430904 T SI 200430904T SI 200430904 T SI200430904 T SI 200430904T SI 1660491 T1 SI1660491 T1 SI 1660491T1
Authority
SI
Slovenia
Prior art keywords
benzthiazole
benzimidazole
benzoxazole derivatives
lta4h modulators
lta4h
Prior art date
Application number
SI200430904T
Other languages
English (en)
Inventor
Frank U Axe
Scott D Bembenek
Christopher R Butler
James P Edwards
Anne M Fourie
Cheryl A Grice
Brad M Savall
Kevin L Tays
Jianmei Wei
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SI1660491T1 publication Critical patent/SI1660491T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Biomedical Technology (AREA)
  • Materials Engineering (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SI200430904T 2003-07-28 2004-07-27 Benzimidazolni, benztiazolni in benzoksazolni derivati in njihova uporaba kot modulatorji LTA4H SI1660491T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49071003P 2003-07-28 2003-07-28
EP04779219A EP1660491B1 (en) 2003-07-28 2004-07-27 Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
PCT/US2004/024050 WO2005012296A1 (en) 2003-07-28 2004-07-27 Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators

Publications (1)

Publication Number Publication Date
SI1660491T1 true SI1660491T1 (sl) 2009-02-28

Family

ID=34115427

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200430927T SI1660492T1 (sl) 2003-07-28 2004-07-27 Benzimidazolni, benztiazolni in benzoksazolni derivati in njihova uporaba kot modulatorji LTA4H
SI200430904T SI1660491T1 (sl) 2003-07-28 2004-07-27 Benzimidazolni, benztiazolni in benzoksazolni derivati in njihova uporaba kot modulatorji LTA4H

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200430927T SI1660492T1 (sl) 2003-07-28 2004-07-27 Benzimidazolni, benztiazolni in benzoksazolni derivati in njihova uporaba kot modulatorji LTA4H

Country Status (29)

Country Link
US (2) US20050043378A1 (sl)
EP (2) EP1660492B1 (sl)
JP (2) JP2007500703A (sl)
KR (2) KR101149379B1 (sl)
CN (2) CN100591679C (sl)
AR (2) AR045729A1 (sl)
AT (2) ATE405562T1 (sl)
AU (2) AU2004261610B2 (sl)
BR (2) BRPI0412345A (sl)
CA (2) CA2534212A1 (sl)
CY (1) CY1108560T1 (sl)
DE (2) DE602004016002D1 (sl)
DK (2) DK1660491T3 (sl)
ES (2) ES2313079T3 (sl)
HK (2) HK1092790A1 (sl)
HR (2) HRP20060039A2 (sl)
IL (1) IL173372A (sl)
MY (1) MY145080A (sl)
NO (2) NO20060771L (sl)
NZ (2) NZ544970A (sl)
PL (2) PL1660491T3 (sl)
PT (2) PT1660492E (sl)
RU (2) RU2359970C2 (sl)
SG (2) SG130192A1 (sl)
SI (2) SI1660492T1 (sl)
TW (2) TW200520756A (sl)
UA (2) UA82888C2 (sl)
WO (2) WO2005012297A1 (sl)
ZA (2) ZA200601720B (sl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004261610B2 (en) * 2003-07-28 2010-05-20 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as LTA4H modulators
CA2603122A1 (en) * 2005-03-31 2006-10-05 Janssen Pharmaceutica N.V. Phenyl and pyridyl lta4h modulators
KR101411167B1 (ko) 2005-04-13 2014-06-23 아스텍스 테라퓨틱스 리미티드 하이드록시벤즈아미드 유도체 및 hsp90 억제제로서의이의 용도
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
ATE497959T1 (de) * 2005-09-02 2011-02-15 Hoffmann La Roche Benzoxazol-, oxazolopyridin-, benzothiazol- und thiazolopyridinderivate
EA017618B1 (ru) * 2005-09-21 2013-01-30 Декод Дженетикс Ехф Биарилзамещенные гетероциклические ингибиторы lta4h для лечения воспаления
EP1968961A2 (en) * 2005-12-21 2008-09-17 Decode Genetics EHF Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
CA2634699A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
AU2006327245A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf Biaryl substituted nitrogen containing heterocycle inhibitors of LTA4H for treating inflammation
HUE031972T2 (en) * 2005-12-29 2017-08-28 Celtaxsys Inc Diamin derivatives as leukotriene A4 hydrolase inhibitors
WO2007085357A1 (en) * 2006-01-30 2007-08-02 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
MX2008016008A (es) * 2006-06-16 2009-01-16 Lundbeck & Co As H Formas cristalinas de 4-[2-(4-metilfenilsulfonil)-fenil] piperidina con inhibicion combinada de la recaptacion de serotonina y norepinefrina para el tratamiento del dolor neuropatico.
WO2008019302A1 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Pyrazolylphenyl and pyrrolylphenyl inhibitors of lta4h for treating inflammation
WO2008019306A2 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
US7728032B2 (en) * 2006-08-04 2010-06-01 Decode Genetics Ehf Phenoxymethylalkyne inhibitors of LTA4H for treating inflammation
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited 複合薬剤
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
CL2008000468A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras.
ES2352880T3 (es) * 2007-03-08 2011-02-23 Irm Llc Compuestos y composiciones como moduladores de la actividad de gpr119.
JPWO2008120710A1 (ja) * 2007-03-30 2010-07-15 パナソニック電工株式会社 活動強度計
TW200932236A (en) * 2007-10-31 2009-08-01 Janssen Pharmaceutica Nv Aryl-substituted bridged diamines as modulators of leukotriene A4 hydrolase
CN101969951B (zh) * 2007-11-16 2012-10-31 雅培制药有限公司 化合物在制备治疗关节炎的药物中的方法
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
EP2336125B1 (en) * 2008-04-11 2013-01-09 Janssen Pharmaceutica N.V. Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase
CA2722772C (en) 2008-04-28 2020-12-22 Janssen Pharmaceutica N.V. Benzoimidazoles as prolyl hydroxylase inhibitors
CA2761881C (en) * 2009-05-14 2017-04-04 Janssen Pharmaceutica Nv Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
CN102442962A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-烷基四氮唑的生产方法
CN102442961A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-甲基四氮唑的生产方法
JP6122862B2 (ja) 2011-10-25 2017-04-26 ヤンセン ファーマシューティカ エヌ.ベー. 1−(5,6−ジクロロ−1h−ベンゾ[d]イミダゾール−2−イル)−1h−ピラゾール−4−カルボン酸のメグルミン塩製剤
RU2686101C2 (ru) 2013-03-12 2019-04-24 Селтакссис, Инк. Способы ингибирования лейкотриен- а4-гидролазы
EP2968265A4 (en) 2013-03-14 2016-12-28 Celtaxsys Inc INHIBITORS OF THE LEUKOTRIEN A4 HYDROLASE
BR112015022226A2 (pt) 2013-03-14 2017-07-18 Celtaxsys Inc inibidores de leucotrieno a4 hidrolase
AU2014239567B2 (en) 2013-03-14 2017-12-14 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
MX2016007566A (es) * 2013-12-17 2016-10-03 Lilly Co Eli Derivados de amina ciclica de fenoxietilo y su actividad como moduladores de receptor ep4.
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
SG10201911849SA (en) 2015-06-09 2020-01-30 Abbvie Inc Nuclear receptor modulators
CN117887794A (zh) 2016-12-21 2024-04-16 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的方法
CN107663192B (zh) * 2017-11-03 2019-05-10 梯尔希(南京)药物研发有限公司 一种雷贝拉唑杂质的制备方法
CA3102077A1 (en) 2018-05-31 2019-12-05 Sanjeev AHUJA Method of reducing pulmonary exacerbations in respiratory disease patients
KR20210123321A (ko) * 2019-01-11 2021-10-13 내기스 파마슈티컬스 인코포레이티드 류코트리엔 합성 억제제
CN110026557B (zh) * 2019-05-28 2021-08-27 南方科技大学 一种混合固体颗粒重熔的直写装置及成型方法
EP4247374A1 (en) * 2020-11-19 2023-09-27 Telo Therapeutics, Inc. Small molecule compounds and compositions
CN113683491A (zh) * 2021-09-01 2021-11-23 王传良 一种4-(2-溴乙基)苯酚的制备方法
CN113735798B (zh) * 2021-09-27 2022-07-12 安徽美致诚药业有限公司 一种盐酸罗沙替丁醋酸酯的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) * 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
CA1319144C (en) * 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
IT1240598B (it) * 1990-03-13 1993-12-17 Mini Ricerca Scient Tecnolog Derivati amminici ad azione antifungina
US5585492A (en) 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5925654A (en) * 1997-03-12 1999-07-20 G.D. Searle & Co. LTA4 , hydrolase inhibitors
CA2322163A1 (en) * 1998-02-25 1999-09-02 John Mckew Inhibitors of phospholipase a2
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US20040110757A1 (en) * 2002-03-21 2004-06-10 Thomas Arrhenius Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
AU2004261610B2 (en) * 2003-07-28 2010-05-20 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as LTA4H modulators
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
MX2007011273A (es) * 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
CL2008000468A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras.

Also Published As

Publication number Publication date
AU2004261610A1 (en) 2005-02-10
HK1092790A1 (en) 2007-02-16
CN1860117A (zh) 2006-11-08
IL173372A (en) 2010-11-30
IL173372A0 (en) 2006-06-11
UA82888C2 (en) 2008-05-26
US20050043379A1 (en) 2005-02-24
PL1660492T3 (pl) 2009-01-30
AU2004261628B2 (en) 2011-05-12
NZ544938A (en) 2009-05-31
BRPI0413072A (pt) 2006-10-03
AR045730A1 (es) 2005-11-09
ES2311858T3 (es) 2009-02-16
ATE403654T1 (de) 2008-08-15
UA87986C2 (uk) 2009-09-10
DE602004016002D1 (de) 2008-10-02
KR20060057593A (ko) 2006-05-26
SG130192A1 (en) 2007-03-20
NZ544970A (en) 2009-02-28
NO20060771L (no) 2006-04-21
WO2005012296A1 (en) 2005-02-10
DK1660492T3 (da) 2008-11-03
HK1090359A1 (en) 2006-12-22
TWI362383B (en) 2012-04-21
WO2005012297A9 (en) 2007-01-04
RU2006102508A (ru) 2006-07-27
AU2004261610B2 (en) 2010-05-20
MY145080A (en) 2011-12-15
ZA200601720B (en) 2007-11-28
DE602004015620D1 (de) 2008-09-18
HRP20060041B1 (hr) 2014-06-06
AR045729A1 (es) 2005-11-09
CA2534212A1 (en) 2005-02-10
PT1660491E (pt) 2008-10-10
BRPI0412345A (pt) 2006-10-03
KR101149379B1 (ko) 2012-06-28
HRP20060039A2 (en) 2006-08-31
CN1856490A (zh) 2006-11-01
ZA200601716B (en) 2007-05-30
AU2004261628A1 (en) 2005-02-10
ES2313079T3 (es) 2009-03-01
KR20060054408A (ko) 2006-05-22
EP1660491B1 (en) 2008-08-06
JP2007500703A (ja) 2007-01-18
US20050043378A1 (en) 2005-02-24
DK1660491T3 (da) 2008-11-10
SI1660492T1 (sl) 2009-02-28
SG129449A1 (en) 2007-02-26
PT1660492E (pt) 2008-11-13
CN100591679C (zh) 2010-02-24
WO2005012297A1 (en) 2005-02-10
RU2006102510A (ru) 2006-07-27
JP4726238B2 (ja) 2011-07-20
TW200523255A (en) 2005-07-16
NO20060823L (no) 2006-03-15
TW200520756A (en) 2005-07-01
EP1660491A1 (en) 2006-05-31
PL1660491T3 (pl) 2009-01-30
EP1660492A1 (en) 2006-05-31
RU2373204C2 (ru) 2009-11-20
EP1660492B1 (en) 2008-08-20
ATE405562T1 (de) 2008-09-15
CY1108560T1 (el) 2014-04-09
RU2359970C2 (ru) 2009-06-27
JP2007500706A (ja) 2007-01-18
CA2534228A1 (en) 2005-02-10
HRP20060041A2 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
HK1090359A1 (en) Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
IL232313A0 (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the aforementioned
HK1083831A1 (en) Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
IL172894A0 (en) Indol-6-sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators
DE60328481D1 (de) Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
PL374693A1 (en) Novel benzimidazole derivatives
DE60335031D1 (de) Befestigter anordnungskörper, verbinder und hydraulikzylindereinheit
IL172891A0 (en) Indol-5-yl-sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators
PT1626964E (pt) Novos derivados de benzimidazole
HK1092877A1 (en) Dye-containing polarizer
AU2003278814A8 (en) Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof
IL175137A0 (en) Bace455, an alternative splice variant of the human beta-secretase
IL172750A0 (en) Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators
TWI348382B (en) N-acetylglucosamine derivatives, and the use thereof
SI1532141T1 (sl) 2-pirolidin-2-il-(1,3,4)-oksadiazolni derivati in njihova uporaba kot antidepresivi
AU2003285498A1 (en) Benzoxazole, benzthiazole and benzimidazole derivatives useful as heparanase inhibitors
ME01506B (me) MODULATORI INDOLAMIN 2,3-DIOKSIGENAZE l POSTUPCI UPOTREBE ISTIH
EE04957B1 (et) Kompositsioon ja selle kasutamine raviva, profülaktilise ja kosmeetilise vahendina
DOP2002000500A (es) Benzamida, heteroarilamida y amidas inversas